About Exact Sciences Corporation (NASDAQ:EXAS)
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:EXAS
- CUSIP: 30063P10
- Web: www.exactsciences.com
- Market Cap: $5.83 billion
- Outstanding Shares: 119,096,000
- 50 Day Moving Avg: $45.77
- 200 Day Moving Avg: $37.38
- 52 Week Range: $13.05 - $50.65
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -68.03
- P/E Growth: -1.87
- Annual Revenue: $169.37 million
- Price / Sales: 34.44
- Book Value: $4.54 per share
- Price / Book: 10.79
- EBITDA: ($129,740,000.00)
- Net Margins: -83.08%
- Return on Equity: -36.36%
- Return on Assets: -32.85%
- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 16.82%
- Quick Ratio: 16.42%
- Average Volume: 1.64 million shs.
- Beta: 0.75
- Short Ratio: 7.98
Frequently Asked Questions for Exact Sciences Corporation (NASDAQ:EXAS)
What is Exact Sciences Corporation's stock symbol?
Exact Sciences Corporation trades on the NASDAQ under the ticker symbol "EXAS."
How were Exact Sciences Corporation's earnings last quarter?
Exact Sciences Corporation (NASDAQ:EXAS) announced its earnings results on Tuesday, July, 25th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.10. The business had revenue of $57.65 million for the quarter, compared to analysts' expectations of $47.73 million. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. View Exact Sciences Corporation's Earnings History.
When will Exact Sciences Corporation make its next earnings announcement?
Where is Exact Sciences Corporation's stock going? Where will Exact Sciences Corporation's stock price be in 2017?
13 brokers have issued 12-month price objectives for Exact Sciences Corporation's shares. Their forecasts range from $28.00 to $60.00. On average, they anticipate Exact Sciences Corporation's stock price to reach $44.92 in the next twelve months. View Analyst Ratings for Exact Sciences Corporation.
What are analysts saying about Exact Sciences Corporation stock?
Here are some recent quotes from research analysts about Exact Sciences Corporation stock:
- 1. According to Zacks Investment Research, "EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. " (9/26/2017)
- 2. Cowen and Company analysts commented, "Colon cancer is the #2 cause of cancer death in the US, yet compliance with screening guidelines is low. Exact Sciences' Cologuard is less invasive than colonoscopy, more accurate than alternatives, FDA approved, in guidelines, and increasingly reimbursed. EXAS is targeting $4B of a ~$15B annual market opportunity. The 5-year revenue CAGR is forecast at ~50%. Initiate at Outperform with a $30 PT." (3/27/2017)
Are investors shorting Exact Sciences Corporation?
Exact Sciences Corporation saw a decrease in short interest during the month of September. As of September 15th, there was short interest totalling 16,290,094 shares, a decrease of 11.3% from the August 31st total of 18,365,552 shares. Based on an average daily trading volume, of 1,406,353 shares, the short-interest ratio is currently 11.6 days. Currently, 14.0% of the company's shares are sold short.
Who are some of Exact Sciences Corporation's key competitors?
Some companies that are related to Exact Sciences Corporation include Alnylam Pharmaceuticals (ALNY), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), Qiagen N.V. (QGEN), Alkermes PLC (ALKS), Icon Plc (ICLR), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), Galapagos NV (GLPG), Bio-Techne Corp (TECH), Puma Biotechnology (PBYI), PAREXEL International Corporation (PRXL), ACADIA Pharmaceuticals (ACAD), FibroGen (FGEN), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX) and Ligand Pharmaceuticals Incorporated (LGND).
Who are Exact Sciences Corporation's key executives?
Exact Sciences Corporation's management team includes the folowing people:
- Kevin T. Conroy, Chairman of the Board, President, Chief Executive Officer
- Jeffrey Thomas Elliott, Chief Financial Officer
- Maneesh K. Arora, Chief Operating Officer, Senior Vice President, Director
- Graham Peter Lidgard Ph.D., Senior Vice President, Chief Scientific Officer
- D. Scott Coward, Senior Vice President, General Counsel, Secretary
- David A. Thompson, Lead Independent Director
- Thomas D. Carey, Independent Director
- James E. Doyle, Independent Director
- John A. Fallon M.D., Independent Director
- Daniel J. Levangie, Independent Director
Who owns Exact Sciences Corporation stock?
Exact Sciences Corporation's stock is owned by a number of of institutional and retail investors. Top institutional investors include Skylands Capital LLC (0.20%), Nationwide Fund Advisors (0.12%), Mutual of America Capital Management LLC (0.09%), Strs Ohio (0.05%), Sit Investment Associates Inc. (0.03%) and Fisher Asset Management LLC (0.01%). Company insiders that own Exact Sciences Corporation stock include D Scott Coward, David Thompson, Graham Peter Lidgard, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Napier, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling, Maneesh Arora and Thomas D Carey. View Institutional Ownership Trends for Exact Sciences Corporation.
Who sold Exact Sciences Corporation stock? Who is selling Exact Sciences Corporation stock?
Exact Sciences Corporation's stock was sold by a variety of institutional investors in the last quarter, including Skylands Capital LLC, Nationwide Fund Advisors, Mutual of America Capital Management LLC and Eqis Capital Management Inc.. Company insiders that have sold Exact Sciences Corporation stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Kevin T Conroy and Maneesh Arora. View Insider Buying and Selling for Exact Sciences Corporation.
Who bought Exact Sciences Corporation stock? Who is buying Exact Sciences Corporation stock?
Exact Sciences Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Strs Ohio, Sit Investment Associates Inc., Fisher Asset Management LLC and Stokes & Hubbell Capital Management LLC. Company insiders that have bought Exact Sciences Corporation stock in the last two years include David Thompson, James Edward Doyle, Katherine S Napier, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling and Thomas D Carey. View Insider Buying and Selling for Exact Sciences Corporation.
How do I buy Exact Sciences Corporation stock?
Shares of Exact Sciences Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Exact Sciences Corporation's stock price today?
MarketBeat Community Rating for Exact Sciences Corporation (NASDAQ EXAS)MarketBeat's community ratings are surveys of what our community members think about Exact Sciences Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Exact Sciences Corporation stock can currently be purchased for approximately $48.98.
Consensus Ratings for Exact Sciences Corporation (NASDAQ:EXAS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||3 Hold Ratings, 10 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.77)|
|Consensus Price Target: ||$44.92 (8.28% downside)|Consensus Price Target History for Exact Sciences Corporation (NASDAQ:EXAS)
Analysts' Ratings History for Exact Sciences Corporation (NASDAQ:EXAS)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/19/2017||Bank of America Corporation||Set Price Target||Buy||$40.00 -> $56.00||N/A|
|10/6/2017||Robert W. Baird||Reiterated Rating||Buy||$49.00||N/A|
|10/3/2017||Canaccord Genuity||Reiterated Rating||Buy -> Buy||$45.00 -> $60.00||High|
|9/21/2017||Leerink Swann||Reiterated Rating||Outperform -> Outperform||$45.00 -> $50.00||High|
|7/26/2017||Roth Capital||Boost Price Target||Buy||$40.00 -> $46.00||High|
|7/26/2017||Craig Hallum||Reiterated Rating||Buy||$41.00 -> $46.00||High|
|7/26/2017||Lake Street Capital||Boost Price Target||Hold -> Hold||$30.00 -> $41.00||Medium|
|7/17/2017||BTIG Research||Reiterated Rating||Buy||$35.00 -> $45.00||Low|
|7/7/2017||Benchmark Co.||Set Price Target||Buy||$50.00||Low|
|6/7/2017||Stephens||Set Price Target||Hold||$28.00||Medium|
|6/1/2017||Jefferies Group LLC||Set Price Target||Buy||$35.00||Medium|
|5/31/2017||Cowen and Company||Reiterated Rating||Outperform||$45.00||High|
|5/1/2017||Goldman Sachs Group, Inc. (The)||Set Price Target||Neutral||$21.00 -> $33.00||Medium|
|7/27/2016||Mizuho||Boost Price Target||Neutral||$10.00 -> $15.00||N/A|
|7/15/2016||William Blair||Reiterated Rating||Outperform||$29.00||N/A|
|10/30/2015||Wedbush||Lower Price Target||$7.00 -> $6.50||N/A|
Earnings History for Exact Sciences Corporation (NASDAQ:EXAS)Earnings History by Quarter for Exact Sciences Corporation (NASDAQ EXAS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/25/2017||Q2 2017||($0.37)||($0.27)||$47.73 million||$57.65 million||View||N/A|
|4/27/2017||Q1 2017||($0.41)||($0.32)||$37.38 million||$48.36 million||View||N/A|
|2/21/2017||Q416||($0.39)||($0.34)||$32.53 million||$35.24 million||View||Listen|
|10/26/2016||Q316||($0.43)||($0.36)||$25.24 million||$28.10 million||View||Listen|
|7/26/2016||Q216||($0.55)||($0.46)||$18.54 million||$21.20 million||View||Listen|
|5/3/2016||Q116||($0.52)||($0.49)||$15.17 million||$14.80 million||View||N/A|
|2/24/2016||Q415||($0.47)||($0.41)||$14.96 million||$14.40 million||View||Listen|
|10/29/2015||Q315||($0.44)||($0.45)||$12.56 million||$12.60 million||View||Listen|
|7/20/2015||Q215||($0.45)||($0.44)||$7.96 million||$8.10 million||View||Listen|
|5/4/2015||Q115||($0.41)||($0.40)||$4.11 million||$4.30 million||View||N/A|
|2/24/2015||Q414||($0.39)||($0.38)||$19.90 million||$1.15 million||View||N/A|
|5/1/2014||Q114||($0.19)||($0.23)||$0.40 million||$0.30 million||View||N/A|
|2/20/2014||Q413||($0.19)||($0.17)||$1.02 million||$1.00 million||View||N/A|
|10/29/2013||Q313||($0.18)||($0.16)||$1.02 million||$1.00 million||View||N/A|
|7/23/2013||Q2 2013||($0.18)||($0.19)||$1.02 million||$1.00 million||View||N/A|
|5/1/2013||Q1 2013||($0.20)||($0.17)||$1.02 million||$1.00 million||View||N/A|
|2/20/2013||Q4 2012||($0.18)||($0.22)||$1.04 million||$1.00 million||View||N/A|
|10/30/2012||Q312||($0.21)||($0.21)||$1.03 million||$1.04 million||View||N/A|
Earnings Estimates for Exact Sciences Corporation (NASDAQ:EXAS)
2017 EPS Consensus Estimate: ($1.47)
2018 EPS Consensus Estimate: ($1.07)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Exact Sciences Corporation (NASDAQ:EXAS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Exact Sciences Corporation (NASDAQ:EXAS)
Insider Ownership Percentage: 4.00%Insider Trades by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)
Institutional Ownership Percentage: 85.23%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/2/2017||D Scott Coward||SVP||Sell||29,115||$47.16||$1,373,063.40|| |
|10/2/2017||Graham Peter Lidgard||Insider||Sell||81,025||$47.16||$3,821,139.00|| |
|9/5/2017||Graham Peter Lidgard||Insider||Sell||75,683||$40.81||$3,088,623.23|| |
|9/1/2017||Graham Peter Lidgard||Insider||Sell||45,775||$41.49||$1,899,204.75|| |
|8/17/2017||Thomas D Carey||Director||Buy||2,500||$37.71||$94,275.00|| |
|7/31/2017||Jeffrey Thomas Elliott||CFO||Sell||5,846||$39.41||$230,390.86|| |
|7/3/2017||D Scott Coward||SVP||Sell||1,987||$35.21||$69,962.27|| |
|4/3/2017||D Scott Coward||SVP||Sell||1,543||$23.74||$36,630.82|| |
|3/13/2017||D Scott Coward||SVP||Sell||1,983||$21.16||$41,960.28|| |
|3/13/2017||Kevin T Conroy||Insider||Sell||12,059||$21.16||$255,168.44|| |
|3/13/2017||Maneesh Arora||COO||Sell||5,574||$21.16||$117,945.84|| |
|2/27/2017||D Scott Coward||SVP||Sell||7,046||$21.48||$151,348.08|| |
|2/27/2017||Graham Peter Lidgard||Insider||Sell||8,668||$21.51||$186,448.68|| |
|2/27/2017||Maneesh Arora||COO||Sell||11,114||$21.50||$238,951.00|| |
|1/3/2017||D Scott Coward||SVP||Sell||1,535||$13.61||$20,891.35|| |
|12/14/2016||David Thompson||Director||Buy||10,000||$13.84||$138,400.00|| |
|11/15/2016||Kevin T Conroy||Insider||Sell||600,000||$17.46||$10,476,000.00|| |
|11/15/2016||Maneesh Arora||COO||Sell||562,932||$17.46||$9,828,792.72|| |
|9/1/2016||Lionel Sterling||Director||Buy||5,000||$18.10||$90,500.00|| |
|8/3/2016||Katherine S Zanotti||Director||Buy||3,380||$17.93||$60,603.40|| |
|7/26/2016||Graham Peter Lidgard||Insider||Sell||7,383||$14.82||$109,416.06|| |
|7/26/2016||Maneesh Arora||COO||Sell||7,359||$14.82||$109,060.38|| |
|4/1/2016||D Scott Coward||SVP||Sell||1,685||$6.62||$11,154.70|| |
|3/10/2016||D Scott Coward||SVP||Sell||2,175||$6.05||$13,158.75|| |
|3/10/2016||Graham Peter Lidgard||Insider||Sell||3,041||$6.05||$18,398.05|| |
|3/10/2016||Maneesh Arora||COO||Sell||4,042||$6.05||$24,454.10|| |
|3/8/2016||James Edward Doyle||Director||Buy||5,000||$6.43||$32,150.00|| |
|3/3/2016||Katherine S Napier||Director||Buy||3,775||$5.38||$20,309.50|| |
|3/1/2016||Kevin T Conroy||CEO||Buy||50,000||$5.00||$250,000.00|| |
|2/26/2016||Kevin T Conroy||CEO||Sell||6,895||$5.81||$40,059.95|| |
|2/25/2016||Graham Peter Lidgard||Insider||Sell||2,997||$5.52||$16,543.44|| |
|2/25/2016||Maneesh Arora||COO||Sell||4,099||$5.52||$22,626.48|| |
|2/23/2016||Graham Peter Lidgard||Insider||Sell||2,411||$6.39||$15,406.29|| |
|2/23/2016||Kevin T Conroy||CEO||Sell||6,866||$6.39||$43,873.74|| |
|2/23/2016||Maneesh Arora||COO||Sell||2,556||$6.39||$16,332.84|| |
|1/11/2016||David Thompson||Director||Buy||15,000||$6.99||$104,850.00|| |
|2/26/2015||Graham Peter Lidgard||Director||Sell||3,938||$23.44||$92,306.72|| |
|2/26/2015||Kevin T Conroy||CEO||Sell||8,425||$23.44||$197,482.00|| |
|2/26/2015||Maneesh Arora||COO||Sell||3,895||$23.44||$91,298.80|| |
|2/24/2015||Graham Peter Lidgard||Director||Sell||4,037||$22.90||$92,447.30|| |
|2/24/2015||Kevin T Conroy||CEO||Sell||9,798||$22.90||$224,374.20|| |
|2/24/2015||Maneesh Arora||COO||Sell||2,995||$22.90||$68,585.50|| |
|1/2/2015||Graham Peter Lidgard||Insider||Sell||3,363||$26.72||$89,859.36|| |
|1/2/2015||Kevin T Conroy||CEO||Sell||9,484||$26.72||$253,412.48|| |
|1/2/2015||Maneesh Arora||COO||Sell||2,495||$26.72||$66,666.40|| |
|10/29/2014||Graham Peter Lidgard||Insider||Sell||8,015||$24.68||$197,810.20|| |
|7/25/2014||Graham Peter Lidgard||VP||Sell||11,081||$15.99||$177,185.19|| |
|7/25/2014||Kevin T Conroy||CEO||Sell||11,336||$15.99||$181,262.64|| |
|7/25/2014||Maneesh Arora||COO||Sell||9,291||$15.99||$148,563.09|| |
|5/5/2014||William Megan||SVP||Buy||10,000||$11.79||$117,900.00|| |
|2/24/2014||Graham Peter Lidgard||VP||Sell||3,160||$14.07||$44,461.20|| |
|2/24/2014||Kevin Conroy||CEO||Sell||8,708||$14.07||$122,521.56|| |
|2/24/2014||Maneesh Arora||COO||Sell||2,662||$14.07||$37,454.34|| |
|1/2/2014||Graham Peter Lidgard||VP||Sell||10,288||$11.96||$123,044.48|| |
|1/2/2014||Kevin Conroy||CEO||Sell||26,379||$11.96||$315,492.84|| |
|1/2/2014||Maneesh Arora||COO||Sell||8,627||$11.96||$103,178.92|| |
|10/28/2013||Graham Peter Lidgard||VP||Sell||7,430||$11.07||$82,250.10|| |
|9/20/2013||Sally Crawford||Director||Sell||25,000||$12.19||$304,750.00|| |
|11/2/2012||Kevin T Conroy||CEO||Buy||2,000||$9.13||$18,260.00|| |
|11/2/2012||Maneesh Arora||CFO||Buy||1,000||$9.04||$9,040.00|| |
|11/1/2012||Lionel Sterling||Director||Buy||5,500||$9.08||$49,940.00|| |
Headline Trends for Exact Sciences Corporation (NASDAQ:EXAS)
Latest Headlines for Exact Sciences Corporation (NASDAQ:EXAS)
Loading headlines, please wait.
Exact Sciences Corporation (EXAS) Chart for Monday, October, 23, 2017